• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Azitra Inc

    6/18/25 4:10:08 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZTR alert in real time by email
    DEFA14A 1 formdefa14a.htm DEFA14A

     

     

     

    United States

    Securities and Exchange Commission

    Washington, D.C. 20549

     

    SCHEDULE 14A INFORMATION

     

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No.   )

     

    Filed by Registrant ☒

     

    Filed by a party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
       
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ☐ Definitive Proxy Statement
       
    ☒ Definitive Additional Materials
       
    ☐ Soliciting Material Under Rule 14a-12

     

    AZITRA, INC.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒ No fee required.
       
    ☐ Fee paid previously with preliminary materials:
       
    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

      

     

     

     

     

     

    AZITRA, INC.

    21 Business Park Drive

    Branford, Connecticut 06405

    (203) 646-6446

     

    SUPPLEMENT TO PROXY STATEMENT

    RELATED TO ANNUAL MEETING OF STOCKHOLDERS

    TO BE HELD ON JUNE 23, 2025

     

    This proxy statement supplement, dated June 18, 2025 (this “Supplement”), amends and supplements the definitive proxy statement on Schedule 14A (the “Proxy Statement”) filed by Azitra, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on May 29, 2025 and made available to the Company’s stockholders in connection with the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”) to be held virtually on June 23, 2025, at 11:00 a.m. Eastern Time. This Supplement is being filed with the SEC and will be made available to stockholders at www.proxydocs.com/AZTR. We are providing this Supplement to update the voting standard for Proposal 2 – Adoption of an amendment to our Second Amended and Restated Certificate of Incorporation (as amended, the “Certificate of Incorporation”) to increase the authorized number of shares of the Company’s common stock from 100,000,000 shares to 200,000,000 shares (“Proposal 2”) in accordance with Section 242(d)(2) of the Delaware General Corporation Law. Except as described in this Supplement, none of the items or information presented in the Proxy Statement is affected by this Supplement. This Supplement does not provide all of the information that is important to your voting decisions at the Annual Meeting. The Proxy Statement contains other important additional information. We encourage you to carefully read this Supplement together with the Proxy Statement. 

     

    Effective August 1, 2023, Section 242(d)(2) was added to the Delaware General Corporation Law (the “DGCL Amendment”), which changed the voting standard to amend a Delaware corporation’s certificate of incorporation to increase the number of authorized shares of a class of stock listed on a national securities exchange immediately before and after the amendment becomes effective from a majority of the outstanding shares entitled to vote thereon to a majority of the votes cast for the amendment by stockholders entitled to vote thereon. In light of the DGCL Amendment, this Supplement updates the disclosure included in the Proxy Statement relating to the applicable voting standard on Proposal 2. The affirmative vote of the majority of votes cast thereon will be required for the approval of Proposal 2. Stockholders may vote “For” or “Against” Proposal 2, or stockholders may abstain from voting. Abstentions will not be counted as votes cast “For” or “Against” Proposal 2. Brokers will not have discretionary authority to vote on Proposal 2. Any broker non-votes in connection with Proposal 2 will not be counted as votes cast “For” or “Against” such proposal. All references in the Proxy Statement to the voting standard on Proposal 2, including the effects of votes cast “For” or “Against” such proposal and abstentions, are hereby updated accordingly.

     

    If you have already returned your proxy or voting instruction card or provided voting instructions, you do not need to take any action unless you wish to change your vote. You do not need to submit a new proxy card or vote again unless you wish to change your vote. Proxy voting instructions already returned by stockholders will remain valid and will be voted at the Annual Meeting unless revoked. Shares represented by all properly submitted proxies (including those submitted electronically, telephonically and in writing) at any time (either prior to or after the date hereof) before the Annual Meeting will be voted as instructed with respect to Proposal 2. The Board of Directors unanimously recommends that you vote “FOR” the election of each director nominee for Proposal 1 and “FOR” Proposals 2, 3 and 4, each as described in the Proxy Statement. If you have not submitted a proxy to have your shares voted, please submit your proxy as soon as possible. You should submit a proxy to vote your shares of common stock via the Internet, by telephone, or by promptly marking, dating, signing, and returning the enclosed proxy card via mail. Voting instructions are provided on the proxy card delivered to you and included in the Proxy Statement that was provided to you. If you have already submitted your proxy with respect to your shares and you wish to change how your shares will be voted on any matter, you may revoke your proxy before it is voted at the Annual Meeting by (1) submitting another properly completed proxy card with a later date, (2) granting a subsequent proxy through the Internet, (3) submit a proxy to vote by telephone at a later time, (4) send timely written notice to our corporate secretary or (5) virtually attend the Annual Meeting and vote online. Simply attending the meeting will not, by itself, revoke your proxy. Your latest proxy is the one that is counted.

     

     

     

    Get the next $AZTR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AZTR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AZTR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome

      Drug candidate ATR12-351 has been generally safe and well-tolerated with occasional, transient, mild to moderate symptoms at application siteTrial is 50% enrolled; six patients have received ATR12-351, a live precision dermatology therapeutic candidate Azitra presenting at the 2025 BIO International ConventionBRANFORD, Conn., June 17, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced encouraging safety data from the initial clinical trial of its live biotherapeutic candidate, ATR12-351, targeting Netherton syndrome.

      6/17/25 8:02:00 AM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Azitra, Inc. Announces Presentation at the 2025 BIO International Convention

      BRANFORD, Conn., June 10, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the company will present at the BIO International Convention being held June 16-19, 2025, in Boston, Massachusetts. The presentation will highlight recent updates and progress in Azitra's pipeline, including ATR-12, currently in a Phase 1b clinical trial in adult patients with Netherton syndrome and ATR-04, in development for the treatment of moderate to severe EGFRi-associ

      6/10/25 8:33:00 AM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash

      BRANFORD, Conn., May 28, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present a poster describing the Phase 1/2 clinical trial of ATR04-484 in EGFR inhibitor ("EGFRi")-associated rash at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) being held May 30-June 3, 2025 in Chicago. The presentation titled, "Epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity treated with topical application of

      5/28/25 8:33:00 AM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZTR
    SEC Filings

    See more
    • Azitra Inc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders

      8-K - Azitra, Inc. (0001701478) (Filer)

      7/3/25 4:05:46 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Azitra Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Azitra, Inc. (0001701478) (Filer)

      6/23/25 4:10:27 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Azitra Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Azitra, Inc. (0001701478) (Filer)

      6/18/25 5:21:29 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Staskey Norm bought $10,034 worth of shares (47,600 units at $0.21), increasing direct ownership by 1,360% to 51,100 units (SEC Form 4)

      4 - Azitra, Inc. (0001701478) (Issuer)

      4/1/24 9:51:59 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Staskey Norm bought $10,034 worth of shares (47,600 units at $0.21), increasing direct ownership by 1,360% to 51,100 units (SEC Form 4)

      4 - Azitra, Inc. (0001701478) (Issuer)

      4/1/24 9:51:59 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Azitra Inc

      SC 13G/A - Azitra, Inc. (0001701478) (Subject)

      11/14/24 12:56:51 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Azitra Inc

      SC 13G/A - Azitra, Inc. (0001701478) (Subject)

      11/14/24 12:18:21 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Azitra Inc

      SC 13G/A - Azitra, Inc. (0001701478) (Subject)

      11/6/24 4:35:43 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZTR
    Leadership Updates

    Live Leadership Updates

    See more
    • Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer

      BRANFORD, Conn., July 11, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the appointment of Travis Whitfill as Chief Operating Officer. Mr. Whitfill is the cofounder of Azitra and joins from Bios Partners, a venture capital firm focused on investing in early-stage biopharmaceutical companies. "We are delighted to welcome Travis back to Azitra full time, after his tenure of nearly ten years in biotech venture capital," said Francisco Salva, President and CEO of Azitra. "Travis brings a wealth of knowledge in biotech, synthetic biology, and drug development. He will

      7/11/23 4:05:00 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZTR
    Financials

    Live finance-specific insights

    See more
    • Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates

      BRANFORD, Conn., Feb. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2024, and provided a business update. FY 2024 and Recent Business Highlights Initiated a Phase 1b clinical trial investigating ATR-12 in adult Netherton syndrome patients; Initial safety data from first set of Netherton syndrome patients expected in the first half of 2025 with topline data from the Phase 1b trial by year-end 2025Received clearance from the U.S. Food and Drug Administration (FDA) for a first-in-human Phase 1/2 clinical stu

      2/24/25 8:30:00 AM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates

      BRANFORD, Conn., Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended September 30, 2024 and provided a business update. Q3 2024 and Recent Business Highlights: Completed a follow-on offering of $10 million in gross proceedsDosed first Netherton syndrome patient with ATR-12Submitted an IND to the FDA and received IND clearance for ATR-04 to treat skin rash from EGFR inhibitorsReceived Fast Track designat

      11/12/24 5:05:00 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

      Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024, and provided a business update. Q2 2024 and Recent Business Highlights Completed a follow-on offering of $10 million in gross proceeds expected to provide cash runway into 2025. With the recent financing, the company anticipates announcing multiple clinical milestones Strengthened global intellectual property portfolio with newly granted and allowed patents Exhibited positive preclinical data from ATR-04 at the Society of Investigative Dermatology Annual Meeting Pres

      8/12/24 6:23:00 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care